MicroPort NeuroTech™ NUMEN® Coil Embolization System Listed for Reimbursement under Korea’s National Health Insurance System

Seoul, Korea, 3 March 2022 — MicroPort NeuroTech Limited (MicroPort NeuroTech™) has announced that its independently-developed NUMEN® Coil Embolization System (NUMEN®) has received approval by Korea’s Health Insurance Review and Assessment Service (HIRA) as a product eligible for health insurance reimbursement in Korea.

As a third-party organization for assessment and regulation, HIRA is an integral component of Korea’s national health insurance system, responsible for developing health insurance catalogs, reviewing medical expenditures and processing medical insurance settlement requests from healthcare institutions, amongst many other responsibilities. Medical devices must be approved by HIRA before they can be marketed in Korea. MicroPort NeuroTech™ NUMEN® has been approved for entry into the Korean health insurance scheme and for inclusion into the reimbursement list. This means that NUMEN® is not only approved for use in Korean hospitals, but also reimbursable under the national health insurance program.

As a new generation detachable coil embolization system, NUMEN® features stable embolization and dense packing. NUMEN®’s ultra-fine platinum-tungsten coil and unique 3D structure offer a combination of flexibility and support which can minimize pressure on the aneurysm wall and ensure safe embolization. NUMEN® is available in various lengths, allowing doctors to select the most appropriate coil for precision embolization based on each patient’s specific condition.

NUMEN® was approved for marketing in China in 2020. It received the CE Marking in Europe, registration permission from Ministry of Food and Drug Safety (MFDS) in Korea and approval from the Food and Drug Administration (FDA) in the United States in 2021. The first overseas implantation of NUMEN® was completed in August 2021 and healthcare professionals praised its stable performance and positive clinical outcomes. The approval of NUMEN® to be listed for reimbursement under the Korean national health insurance system is a crucial step in MicroPort NeuroTech™’s entry into the Korean market and its continued expansion in the international market.

MicroPort NeuroTech™ remains committed to its brand philosophy ‘The Patient Always Comes First’, and will continue to provide high quality and accessible total medical solutions for stroke patients throughout the world.

About MicroPort NeuroTech™

MicroPort NeuroTech Limited is a subsidiary of MicroPort Scientific Corporation (00853.HK). Founded in 2012, MicroPort NeuroTech™ is a high-end medical device company focused on neuro-intervention that provides a range of neuro-interventional products to treat a variety of brain conditions. In the future, MicroPort NeuroTech™ will invest more resources in innovation and development to provide more high-quality and innovative solutions for cerebrovascular and neuro interventions for doctors and patients.